Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul-Sep;7(3):119-123.
doi: 10.4103/GMIT.GMIT_35_18. Epub 2018 Aug 23.

Efficacy of Hormonal Therapies for Decreasing Uterine Volume in Patients with Adenomyosis

Takashi Matsushima  1 , Shigeo Akira  2 , Takehiko Fukami  1 , Koichi Yoneyama  1 , Toshiyuki Takeshita  2
Affiliations

Efficacy of Hormonal Therapies for Decreasing Uterine Volume in Patients with Adenomyosis

Takashi Matsushima et al. Gynecol Minim Invasive Ther. 2018 Jul-Sep.

Abstract

Study objective: The aim of this study is to evaluate the efficacy of hormonal therapies for inhibiting an increase in uterine volume in patients with adenomyosis.

Design: This was retrospective cohort study.

Setting: This study was conducted at Nippon Medical School Musashikosugi Hospital.

Patients: A total of 28 women diagnosed with adenomyosis using magnetic resonance imaging.

Methods: After providing informed consent, patients were treated with gonadotropin-releasing hormone agonist (GnRHa group), a low-dose estrogen and progestin combination (LEP group), or dienogest (DNG group) for ≥16 weeks. Uterine volume was assessed using the formula for an ovoid; uterine volumes before and after 16 weeks of treatment were compared. A <5% increase in uterine volume at 16 weeks was considered to reflect inhibition of uterine volume increase and efficacy of the medication. We compared the efficacy rate among the groups.

Results: In the GnRHa group, a significant reduction in uterine volume was noted, from 307.4 ± 230.1 to 177.9 ± 142.1 cm3 (P < 0.001). In the LEP and the DNG groups, there was no significant change (LEP: 226.7 ± 116.6 cm3 pre-treatment and 230.5 ± 128.6 cm3 post-treatment, P = 0.85; DNG: 232.6 ± 117.8 cm3 pre-treatment and 262.1 ± 136.8 cm3 post-treatment, P = 0.37). The number of responders (efficacy rate) in the GnRHa group, LEP group, and DNG group was 25/26 (96.2%), 7/15 (46.7%), and 6/11 (54.5%), respectively. The efficacy rate of GnRHa therapy was significantly higher than that of LEP or DNG therapy (P < 0.001 and P = 0.005, respectively).

Conclusion: We conclude that the efficacy of GnRHa in reducing uterine volume should be considered when prescribing hormone therapy for adenomyosis.

Keywords: Adenomyosis; dienogest; ethinyl estradiol; ferrous fumarate drug combination; gonadotropin-releasing hormone; norethindrone acetate.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Uterine volume in each treatment group before and after 16 weeks of hormonal therapy. Uterine volumes before and after administration of each hormonal treatment indicates that uterine volume was significantly reduced in the GnRHa group, but in the LEP and DNG groups, there was a slight increase in uterine volume after treatment, but this increase was not statistically significant. *: P < 0.001
Figure 2
Figure 2
Efficacy rate for each hormonal treatment group. The GnRHa group had a significantly higher efficacy rate than that seen in the LEP and DNG groups (P < 0.001, P = 0.005). Efficacy ratio. GnRHa: 96.2% (25/26). LEP: 46.7% (7/15)*, DNG: 54.5% (6/11)**, *<0.001, ** = 0.005. GnRHa: Gonadotropin-releasing hormone agonist, LEP: Low-dose estrogen-progestin combinations, DNG: Dienogest
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Benagiano G, Brosens I, Habiba M. Adenomyosis: A life-cycle approach. Reprod Biomed Online. 2015;30:220–32. - PubMed
    1. Pontis A, D’Alterio MN, Pirarba S, de Angelis C, Tinelli R, Angioni S, et al. Adenomyosis: A systematic review of medical treatment. Gynecol Endocrinol. 2016;32:696–700. - PubMed
    1. Li T, Xu XX, Dai Y, Zhang JJ, Lang JH, Leng JH, et al. Menorrhagia and uterine volume associated with lower urinary tract symptoms in patients with adenomyosis. Chin Med J (Engl) 2017;130:1552–6. - PMC - PubMed
    1. Shiota M, Kotani Y, Umemoto M, Tobiume T, Tsuritani M, Shimaoka M, et al. Deep-vein thrombosis is associated with large uterine fibroids. Tohoku J Exp Med. 2011;224:87–9. - PubMed
    1. Akira S, Iwasaki N, Ichikawa M, Mine K, Kuwabara Y, Takeshita T, et al. Successful long-term management of adenomyosis associated with deep thrombosis by low-dose gonadotropin-releasing hormone agonist therapy. Clin Exp Obstet Gynecol. 2009;36:123–5. - PubMed